At the request of Denmark, the Committee held an exchange of views on the classification of a product as food for special medical purposes (FSMP). The product in question is a tablet for the dietary management of lack of alphalipoic acid in diabetic neuropathy. Member States noted that similar products are placed on the market in their territory as food supplements, so that patients suffering from diabetic neuropathy can satisfy their specific nutritional requirements by modifying the normal diet through consumption of the food supplements. Therefore, the Commission did not find it necessary to adopt an interpretation decision pursuant to Article 3. For further details, see the minutes: https://ec.europa.eu/food/sites/food/files/reg-com_gfl_20161010_sum.pdf
